Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
H Liu, G Han, M Peng, Y Weng, J Yuan, G Yang… - Current Medical …, 2017 - Springer
With the development of molecular pathology, many types of epidermal growth factor
receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase …
receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase …
Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non …
Q Zhang, Y Cui, J Zhang… - Experimental and …, 2020 - spandidos-publications.com
Patients with epidermal growth factor receptor (EGFR)‑sensitive mutations generally have a
significantly higher objective response rate (ORR) and longer progression‑free survival …
significantly higher objective response rate (ORR) and longer progression‑free survival …
[HTML][HTML] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
I Okamoto, S Morita, N Tashiro, F Imamura, A Inoue… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
J Xu, B Jin, T Chu, X Dong, H Yang, Y Zhang, D Wu… - Lung cancer, 2016 - Elsevier
Introduction There are a number of uncommon EGFR mutations whose associations with
TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple …
TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple …
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR …
HA Jung, S Park, JM Sun, SH Lee, JS Ahn, MJ Ahn… - Biology, 2020 - mdpi.com
Simple Summary The present study showed the comprehensive analysis of disease
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
DH Koo, K Kim, CM Choi, DH Lee, JC Lee… - Cancer chemotherapy …, 2015 - Springer
Purpose Although epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs)
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
[HTML][HTML] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
J Shi, H Yang, T Jiang, X Li, C Zhao… - Chinese Journal of …, 2017 - ncbi.nlm.nih.gov
Objective Data on the clinical activity of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon …
kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon …
Treatment of patients with non-small-cell lung cancer with uncommon EGFR mutations in clinical practice
Y Yamada, T Tamura, Y Yamamoto… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: To describe real clinical outcomes in patients with non-small cell lung
cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials …
cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials …
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase …
SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
相关搜索
- egfr tyrosine kinase inhibitors
- growth factor receptor mutations
- egfr mutations nsclc patients
- lung cancer treatment of patients
- treatment timing egfr mutation
- pulmonary adenocarcinoma with egfr mutation
- common egfr mutations
- egfr mutations retrospective analysis
- lung cancer comparison of the effects
- lung cancer clinical practice
- world treatment patient cohort
- treatment of patients clinical practice
- comparison of the characteristics egfr tyrosine
- egfr tkis nsclc patients